Pulminiq delay
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron anticipates a three-month delay in FDA's decision on its inhaled cyclosporine product Pulminiq because "FDA...has requested additional analysis of the pivotal study," the firm says Jan. 26. "As a result, the...action letter date will be extended to July," it notes. Chiron submitted an NDA for prevention of lung transplant rejection Oct. 14, 2004 (1Pharmaceutical Approvals Monthly Nov. 1, 2004, p. 29) and was granted a priority review...
You may also be interested in...
Chiron Submits Inhaled Immunosuppressant Pulminiq NDA For Lung Transplant
Chiron is requesting a priority review for its Pulminiq NDA, submitted October 14, which would place the user fee goal date for the aerosolized cyclosporine in April.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.